Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 11:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 307 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NAFLD - Nonalcoholic Fatty Liver Disease Clear all
Completed Early Phase 1 Interventional

A Feasibility Trial of OCM Supplements for the Treatment of NAFLD

NCT05720702
View directory record Official record
Conditions
NAFLD
Interventions
homocysteine (Hcy) lowering supplements
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Not applicable Interventional Results available

Tesamorelin Effects on Liver Fat and Histology in HIV

NCT02196831
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Interventions
tesamorelin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Bethesda, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224

NCT04932512
View directory record Official record
Conditions
Steatohepatitis, Nonalcoholic
Interventions
ION224, Placebo
Drug · Other
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
50
States / cities
Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 13, 2026, 11:37 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis

NCT04175392
View directory record Official record
Conditions
Fatty Liver Disease, Fibrosis, Liver, Cirrhosis, Liver, Steatohepatitis, Nonalcoholic
Interventions
Align Probiotic Supplement Capsule, Placebos
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH

NCT02784444
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis
Interventions
MSDC-0602K, Placebo
Drug
Lead sponsor
Cirius Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
43
States / cities
Chandler, Arizona • Tucson, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Not applicable Interventional

Feasibility of VIIT in Adults With NASH

NCT03861819
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Liver Diseases
Interventions
Vigorous-intensity interval training (VIIT)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 59 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease

NCT05364684
View directory record Official record
Conditions
NAFLD, Nonalcoholic Fatty Liver, NASH - Nonalcoholic Steatohepatitis
Interventions
LUM-201
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 1 Interventional

Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis

NCT05680233
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Interventions
OA-235i (4 mg), OA-235i (8 mg), OA-235i (16 mg), OA-235i (30 mg), OA-235i (40 mg), OA-235i or placebo
Drug
Lead sponsor
Oasis Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT03812029
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Vonafexor, Placebo
Drug · Other
Lead sponsor
Enyo Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
North Little Rock, Arkansas • Lakewood Rch, Florida • Ocoee, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

NCT06482112
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
Interventions
Efinopegdutide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
36
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 13, 2026, 11:37 PM EDT
Recruiting No phase listed Observational

Accurate Point of Care Liver Disease Diagnostics (Phase 2)

NCT07518784
View directory record Official record
Conditions
MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease)
Interventions
LiverScope® exam, MR exam, Blood draw, Body measurements, Questionnaire
Diagnostic Test · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT04166773
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
47
States / cities
Birmingham, Alabama • Chandler, Arizona • Fresno, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

NCT03976401
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EFX, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Huntington Park, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Not applicable Interventional Results available

LAGB as a Treatment for Morbid Obesity in Adolescents

NCT01045499
View directory record Official record
Conditions
Morbid Obesity, Obstructive Sleep Apnea Syndrome, Metabolic Syndrome, Insulin Resistance, Nonalcoholic Fatty Liver Disease
Interventions
Laparoscopic adjustable gastric banding (Allergan Lap Band)
Device
Lead sponsor
Jeffrey L Zitsman, MD
Other
Eligibility
13 Years to 19 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 1Phase 2 Interventional

Fatty Liver Disease in Obese Children

NCT02117700
View directory record Official record
Conditions
Obesity, Nonalcoholic Fatty Liver Disease, Cardiovascular Disease
Interventions
N-acetyl cysteine 600 mg once/day, N-acetyl cysteine 600mg twice/day, Placebo twice/day
Dietary Supplement · Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 13, 2026, 11:37 PM EDT
Active, not recruiting Not applicable Interventional

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

NCT01047735
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis

NCT03486912
View directory record Official record
Conditions
Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
85
States / cities
Madison, Alabama • Chandler, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 13, 2026, 11:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER

NCT04165343
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Interventions
Positron Emission Tomography (PET) on EXPLORER, Magnetic Resonance Imaging, Echocardiogram and Electrocardiogram, Blood test
Radiation · Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 13, 2026, 11:37 PM EDT
Withdrawn Not applicable Interventional

A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH)

NCT03163810
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Erchonia Verju Laser, Erchonia EVRL Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

NCT03439254
View directory record Official record
Conditions
Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Interventions
Obeticholic acid (10 mg), Obeticholic acid (10 mg to 25 mg), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
120
States / cities
Dothan, Alabama • Madison, Alabama • Chandler, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 13, 2026, 11:37 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Novel MRE Technique to Assess a Risk Factor for Liver Cancer

NCT05165446
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Not listed
Lead sponsor
Natalie Torok
Other
Eligibility
18 Years to 99 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

NCT04210245
View directory record Official record
Conditions
Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Interventions
aldafermin, Placebo
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
31
States / cities
Glendale, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

NCT05415722
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-501, TERN-101, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
35
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 13, 2026, 11:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD

NCT04494360
View directory record Official record
Conditions
Healthy
Interventions
No intervention
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
830 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Hollywood, Florida • Lenexa, Kansas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 13, 2026, 11:37 PM EDT